by Bo Koppert | Sep 26, 2025 | News
The Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go straight to Phase 3 development. This rare waiver recognizes the global dataset already generated for VMX-C001 and streamlines...
by Bo Koppert | Sep 23, 2025 | News
LEIDEN, The Netherlands, September 15, 2025 / Biotech Newswire / — ProteoNic, a leader in premium vector technology for biologics and cell and gene therapy, today announced the launch of its novel 2G UNic® transposon platform, available for licensing alongside...
